INHIBITORS OF 5-LIPOXYGENASE

Abstract: Certain substituted-4-hydroxy- (or 4-acyloxy-)2H-­ 1,2-benzothiazine 1,1-dioxides having at the 3-position a 2-substituted-1,3,4-oxadiazol-5-yl or a 2-substituted-­ tetrazol-5-yl group useful as selective 5-lipoxygenase pathway inhibitors; and methods for their preparation.

Description: This invention relates to certain substituted-4-hydroxy- and 4-acyloxy-2H-1,2-benzothiazine 1,1-dioxides having at the 3-position a 2-substituted-1,3,4-oxadiazol-5-yl or a 2-substituted-tetrazol-5-yl group which demonstrate selective 5-lipoxygenase (5-LO) pathway inhibitory activity. Arachidonic acid is the biological precursor of a group of endogenous metabolites, the leukotrienes. Said metabolites arise via the action of arachidonate lipoxygenases and give rise to allergic reactions. 5-Lipoxygenase, for example, catalyzes the oxygenation of arachidonic acid at C5. This is the first step in the biosynthesis of slow reacting substance of anaphylaxis (SRS-A), a bronchoconstrictive agent believed to cause allergic asthma in man. Although discovery of the antiinflammatory activity of 1,2-benzothiazines has given rise to intensive investigation of said compounds, especially of the 1,1-dioxide derivatives thereof wherein the substituent at the 3-position is a substituted carboxamide, few people have synthesised 1,2-benzothiazines having a heterocyclic moiety at the 3-position. GB-A-1492716 and GB-A-1492718 disclose certain 1,2-benzothiazine 1,1-dioxides having a 2-(1,2,4-oxadiazol-3-yl) substituent, as anti-inflammatory agents, however no one appears to have disclosed the use of 1,2-benzothiazines as inhibitors of 5-lipoxygenase. The 5-LO inhibiting activity of several structural types of compounds is reported in the literature: 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (AA861), Yoshimoto et al., Biochim. et Biophys. 713 , 470-473 (1982) and analogs thereof; 5,6-methanoleukatriene derivatives including KCN-TEI-6172, and 5,8,11-eicosatrynoic acid (ETYA); 3-amino-1-(m-trifluoromethyl)phenyl-2-pyrazoline (BW 755c), Krishishara et al., FEBS Letters, 143 , 13-16 (1982); 1-phenyl-3-pyrazolidone (Phenidone), Carty et al., Prostaglandins, 19 , 671-679 (1980); 6,9-pyrroloprostacyclin (U-60,257), Bach et al., Prostaglandins, 23 , 759-771 (1982); and tetrazole, acylhydroxylamine, hydroxymethylketone and amide derivatives of unsaturated fatty acids related to arachidonic acid, EP-104,468, published April 14, 1984. The overall medical significance of the problems of bronchoconstriction and pulmonary diseases gives rise to the need for selective and efficient inhibitors of 5-LO in order to prevent, at least to minimise, the formation of SRS-A in man and, as a consequence, to reduce allergic asthma reactions. The 5-LO inhibitors of this invention have formulae I and II wherein, in formula I, R¹ is alkyl having form 1 to 8 carbon atoms or -(CH₂) m -O-(CH₂) n -OR⁶ where m is an integer from 1 to 4, n is an integer from 2 to 4 and R⁶ is alkyl having from one to six carbon atoms; R² is hydrogen, alkanoyl having from 2 to 15 atoms, cycloalkylcarbonyl having from 3 to 8 carbon atoms in the cycloalkyl moiety, benzoyl or benzoyl being ring substituted with F, Cl, Br, I, CF₃, CH₃, NO₂ or CH₃O; and R³ is alkyl having from 1 to 15 carbon atoms, cycloalkyl having from 3 to 8 carbon atoms, phenyl or phenyl substituted with F, Cl, Br; I, CF₃, CH₃, NO₂ or CH₃O; and wherein in formula II, R¹ is as defined above; R⁴ is hydrogen, alkanoyl having from 2 to 15 carbon atoms, benzoyl, or benzoyl ring substituted with F, Cl, Br, I, CF₃, CH₃, NO₂ or CH₃O; and R⁵ is hydrogen, alkyl having from 1 to 15 carbon atoms, alkanoyl having from 2 to 16 carbon atoms, cycloalkylcarbonyl having from 3 to 8 carbon atoms in the cycloalkyl moiety, phenyl(C₁-C₄ alkyl) or benzoyl, said phenylalkyl or benzoyl optionally being ring substituted with F, Cl, Br, I, CF₃, CH₃, NO₂ or CH₃O. Preferred compounds of the invention are those of formula I wherein R¹ is alkyl having from 1 to 4 carbon atoms or methoxyethoxymethyl; R² is hydrogen, alkanoyl having from 2 to 15 carbon atoms, benzoyl, cyclohexylcarbonyl or methoxybenzoyl; and R³ is alkyl having from 7 to 15 carbon atoms, phenyl, methoxyphenyl, tolyl or cyclohexyl; and of formula II, wherein R¹ is alkyl having from 1 to 3 carbon atoms or methoxyethoxymethyl; R⁴ is hydrogen, acetyl or benzoyl; and R⁵ is hydrogen, alkyl having 7 to 15 carbon atoms, benzyl, methylbenzyl or methoxybenzyl. Of particular interest because of their potent and selective 5-LO inhibiting activity are those compounds of formula (I) wherein R¹ is alkyl having from 1 to 3 carbon atoms, R² is benzoyl, cyclohexylcarbonyl or acetyl; and R³ is alkyl having from 9 to 11 carbon atoms, phenyl, methoxyphenyl or tolyl; and those compounds of formula (II) wherein R¹ is alkyl having from 1 to 3 carbon atoms, R⁴ is acetyl, and R⁵ is alkyl having from 8 to 10 carbon atoms, methoxybenzyl or methylbenzyl. Particularly preferred compounds of formula I are those wherein R¹ is ethyl; R² is acetyl, cyclohexylcarbonyl, or benzoyl or R³ is alkyl having from 7 to 11 carbon atoms, phenyl or tolyl. Particularly preferred compounds of formula II are those wherein R¹ is ethyl; R⁴ is acetyl; and R⁵ is alkyl having from 8 to 10 carbon atoms or methylbenzyl. The compounds of this invention are prepared from N-cyanomethylsaccharin [2-cyanomethyl-1,2-benzisothiazol-3 (2H)-one 1,1-dioxide] by the abbreviated reaction sequence presented below: In the first step, N-cyanomethylsaccharin (III) is converted to o-carboalkoxy-N-cyanomethylbenzenesulfonamide (IV) by cleavage of the cyclic imide by reaction with an alkali metal alkoxide of 1-4 carbon atoms in a C 1-4 alkanol solvent. Sodium methoxide-methanol represents the preferred system for the cleavage reaction. In general, the molar ratio of cyclic imide to alkali metal alkoxide varies from 1:1.5 to 1:0.5. The molar ratio of said reactants is not critical. However, in practice, molar ratios of from 1:1.1 to 1:1.05 are favored. Methanol is generally used as solvent regardless of the alkali metal alkoxide used. The reaction is conducted at a temperature of below room temperature and preferably at from 5-10° C in order to minimize side reactions. The product (IV) is isolated by neutralization of the reaction mixture, desirably below room temperature, e.g. from 10-15° C, and the precipitated solid recovered. The second step involves alkylation of the sulfonamide moiety of (IV) with the appropriate halide, R¹-X, wherein X is iodo, chloro or bromo in the presence of an acid acceptor and in a reaction-inert solvent. The reactants are generally reacted together in stoichiometric or approximately stoichiometric amounts at a temperature of from 25° to 5° C. Suitable reaction-inert solvents: i.e., those which do not react to any degree with the reactants and/or products in such a manner as to significantly reduce the yield of a given reaction. Representative of such solvents are acetone, water, N,N-dimethylformamide, methylene chloride, chloroform and mixtures thereof. The choice of acid acceptor is somewhat dependent upon the solvent system used. It is desirable, in order to achieve optimum removal of by-product from the reaction, to use an acid acceptor which is soluble in the solvent system used. However, acid acceptors which are insoluble in the solvent can also be used. Aqueous systems are the more versatile systems in that both inorganic and organic acid acceptors can be used. When using a non-aqueous solvent system, tertiary amines, such as triethylamine, pyridine, N-methylmorpholine, N-ethylpiperidine and N,N-dimethylaniline are suitable acid acceptors. Aqueous systems permit use of the aforementioned bases and also of inorganic bases such as alkali metal hydroxides and carbonates. Inorganic bases can, of course be used in non-aqueous solvents. For example, the inorganic bases enumerated above can be used as acid acceptors in N,N-dimethylformamide as those skilled in the art will recognize. The compounds of formula (IV) and N-substituted derivatives of formula (IV) compounds can, if desired, be isolated by known procedures, or they can be converted to the cyclic compound of formula (V). It is generally preferred to at least obtain the formula (IV) compound in concentrated form before cyclizing it to a formula (V) compound. The cyclization of formula (IV) compounds, (N-unsubstituted or N-substituted derivatives thereof), is readily accomplished by means of alkali metal (C 1-4 )alkoxide (C 1-4 )alkanol and especially of sodium (or potassium) methoxide-methanol in a hydrocarbon solvent such as toluene, benzene, xylene, n-hexane at about room temperature. The cyclized formula (V) compounds are recovered by known procedures as by concentration of the reaction, addition of water to the concentrate followed by acidification thereof and removal of the product by filtration if precipitation thereof occurred, or by extraction with an appropriate water-immiscible solvent. Alternatively, the reaction is not concentrated but is extracted with water and the extract then acidified. Conversion of formula (V) compounds to the tetrazol-5-yl derivatives of formula (VI) is accomplished by reaction of the cyano derivative, formula (V), with azide ion in the presence of an acid addition salt of ammonia or of amines and in a reaction-inert solvent. The azide ion can be derived from a variety of sources. The only criterion appears to be that the particular source chosen be capable of releasing azide ion under the conditions; i.e., solvent, temperature, of a given reaction. Suitable sources of azide ions are inorganic and organic azides. In the case of organic azides, the organic moiety must be strongly electron withdrawing in nature. Representative sources of azide ions are metal azides, especially alkali metal azides, trialkylsilyl azides having from one to four carbon atoms in each of the alkyl groups, such as trimethylsilyl azide and triethylsilyl azide, tetra-n-butylammonium azide, tetramethylguanidinium azide, hydrazoic acid, ammonium azide, trifluoromethylazide, N,N-dimethylanilinium azide, N-methyl-morpholinium azide and triethylammonium azide. The molar ratio of azide to cyano reactant of formula (VI) is generally held in the range of from 1:1 to 6:1. Higher ratios can be used but are generally accompanied by reduced yields of the desired tetrazole product. In practice, molar ratios of 2:1 have been found to afford high yields of the desired tetrazol-5-yl compounds of formula (VI). The presence of from 1 to 5 moles of ammonium chloride or of acid addition salts of amines to azide reactant during the reaction is desirable. The acid addition salts of primary, secondary and tertiary amines can be used. The nature of the acid portion of the acid addition salt is immaterial to the operability of this process. However, certain acid addition salts are favored over others for such reasons as availability, ease of preparation and solubility in the reaction mixture. The suitability of a given amine acid addition salt is easily determined by carrying out the process of this invention using the particular amine acid addition salt. Favored acid addition salts are the salts with mineral acids and organic acids such as alkane sulfonic acids such as methane and ethane sulfonic acids, p-toluenesulfonic acid, benzene-sulfonic acid, napthalenesulfonic acids, alkanoic acids such as acetic, n-butyric, octanoic, benzoic and substituted benzoic acids and cation exchange resins. The preferred amine acid addition salts are the hydrochloride salts of tertiary amines such as triethylamine, tri-n-propylamine, tri-n-butylamine, trimethylamine, N,N-dimethylaniline, N-methylpiperidine and N-methyl-morpholine because of the satisfactory conversions of nitrile to tetrazole they afford in this process. Especially preferred is ammonium chloride. Suitable reaction-inert solvents for this process are N,N-dimethyl formamide (DMF), halogenated hydrocarbons such as trichloroethanes, chloroform, and methylene chloride, ethers such as dioxane, tetrahydrofuran, dimethyl and diethyl ethers of ethyleneglycol and diethylene glycol, macrocylcic polyethers (crown compounds), benzene, xylene, tetralin and pyridine. DMF is a favored solvent in view of the favorable yields it affords and the ease of recovery of the tetrazolyl products therefrom. In order to expedite the reaction the solvent should desirably be one which completely dissolves all reactants. As one skilled in the art appreciates, complete solubility is, however, not necessary. Partial solubility of reactants in the solvent system is sufficient to permit reaction to occur at an acceptable rate. The reaction is generally conducted over the range of from 20° C to 110° C. The favored temperature range is from 25° C to 80° C and the preferred range from 40° C to 70° C. Temperature is not a critical factor and lower or higher temperatures can be employed. Lower temperatures, of course, require longer reaction times than do the higher temperatures. Temperatures above about 110° C. are usually avoided to minimize decomposition of reactants and products. The reaction period depends in part upon the reactants and the solvent system used. As a general rule, the reaction is completed in periods ranging from 2 to 24 hours. In the conversion of formula (V) to formula (VI) compounds, the use of an acid rather than acid addition salts of ammonia or of amines also affords satisfactory reaction. Acids such as those enumerated above under acid addition salts of amines are representative of suitable acids. The tetrazole compounds of formula (VI) are converted to oxadiazoles of formula (I) via the Huisgen reaction. This reaction comprises acylation of the tetrazole (VI) to produce a compound of formula (II-A) or (II). Said acylation is carried out under standard acylation conditions using the appropriate acid, acyl halide or acyl anhydride. Suitable solvents for the acylation reaction are aromatic hydrocarbons such as benzene, toluene or xylene; chlorinated hydrocarbons such as dichloromethane and chloroform. When the acylating agent is a liquid, e.g. acetic anhydride, it is advantageously used in excess to serve both as reactant and solvent. When isolation of the acyl derivative is desired, the reaction is conducted at temperatures ranging from 5°-25° C in order to avoid thermal fragmentation of the tetrazole derivative with loss of nitrogen and ultimate formation of a 1,3,4-oxadizole derivative. Acylation with the appropriate acyl halide is carried out in the presence of an acid acceptor such as pyridine, triethylamine, N-methylmorpholine or N,N-dimethylaniline, at temperatures of from 5°-25° C, in a solvent such as those enumerated above. Alternatively, an excess of the acid acceptor, e.g. pyridine, can be used as solvent. Acylation with an acid is conducted in a solvent such as those enumerated above and in the presence of a dehydrative coupling agent such as dicyclohexylcarbodiimide according to known procedures. The acylation products are isolated, if desired, by conventional methods as by filtration or, if not solid forms, by concentration of the reaction mixture to an oil. In many instances the oily product obtained can be obtained as a solid, or as crystals, by addition of n-hexane or other solvent. When an acyl halide is used as acylating agent in the presence of an excess of acid acceptor, the products are conveniently recovered by diluting the reaction mixture with aqueous acid, e.g. dilute hydrochloric acid, and removal of the solid product by filtration. When excess acid acceptor is not used, dilution of the reaction mixture with an organic solvent and extraction of the resulting solution with aqueous acid (e.g. dilute HCl) and water affords the acylated product. Mono- or diacylated products are produced depending upon the stoichiometric ration of acylating agent to tetrazole reactant of formula (VI). The use of up to one equivalent of acylating agent per mole of formula (VI) compound affords the monoacyl derivative as principal product. Greater amounts of acylating agent favor diacylation; i.e., at the 4-hydroxy group and at the tetrazolyl group. The use of two or more equivalents, of course, favours diacylation. An alternative procedure for acylating formula (VI) compounds comprises reacting said compounds with the appropriate carboxylic acid in the presence of a dehydrative coupling agent such as carbodiimide, ethoxyacetylene, alpha-chlorovinyl ethyl ether, N,N'-carbonyldiimidazole, N-hydroxysuccinimide and 2-ethyl-5-(3-sulfophenyl)-1,2-oxazole-betaine. Preferred as coupling agent is dicyclohexylcarbodiimide. Said dehydrative coupling agents when used to prepare acylated products of this invention are used according to standard procedures. For example, the formula (VI) compound and appropriate acid are reacted in a reaction-inert solvent such as toluene or xylene, at the reflux temperature in the presence of dicyclohexylcarbodiimide. To insure satisfactory yields excesses of carbodiimide and acid, based on the formula (VI) compound, are used. In practice mole ratios of formula (VIII) compound to acid to dicyclohexylcarbodiimide of 1:3:3 have been found satisfactory. The 4-acyl derivatives of compounds of formula (I) are readily converted to the corresponding 4-hydroxy derivatives by alkaline hydrolysis, especially by use of alkali metal alkoxides in an alkanol solvent corresponding to the alkanol from which the alkoxide is derived. The hydrolysis occurs at room temperature. The 4-hydroxy derivative is recovered by removal of the solvent and adjustment of the pH of an aqueous mixture of the residue to about 1.5. The 4-hydroxy formula (I) compounds thus obtained can then be reacylated with a different acylating agent, if desired. The reacylation is carried out according to the conditions described above. The isolated compounds of formula (II) are transformed to formula (I) compounds by heating to an elevated temperature, e.g. from 80°-150° C, in a reaction-inert solvent such as toluene, benzene, xylene, acyl anhydride (excess). Lower temperatures require too large a heating period to be practical. Higher temperatures can, of course, be used but afford no advantage. The oxadizole compounds are recovered by concentration of the reaction mixture, cooling the concentrate to precipitate a solid which is filtered off. The acylation products of formula (II) need not be isolated prior to converting them to oxadiazoles of formula (I). The conversion of formula (VI) to formula (I) compounds can be carried out in situ without isolation of the intermediate compounds of formula (II-B). The reaction comprises acylating the tetrazole of formula (VI), generally with excess acylating agent, e.g. from 2-5 fold excess, over that required to produce the diacyl derivative at an elevated temperature. The same acylating agents and solvent systems as discussed above in connection with the conversion of formula (VI) to formula (I) compounds with isolation of the formula (II) intermediates are used in this one step conversion. The one difference is the temperature of the acylation process which should be carried out at from 80°-150° C to achieve acylation with direct transformation to formula (I) compounds. Compounds of formula II wherein R⁵ is benzyl, methoxybenzyl or methylbenzyl are prepared from formula (II) compounds wherein R⁵ is H by reaction of said formula (II) compound with the appropriate aralkyl halide such as benzyl bromide, 2-methoxybenzyl chloride and 4-methylbenzyl chloride, in a reaction-inert solvent in the presence of an acid acceptor. It is preferred to use an aralkyl bromide as reactant. When an aralkyl chloride is used as reactant, it is advantageous to add a small amount of alkali metal iodide as accelerator because of the relatively lower reactivity of aralkyl chlorides compared to aralkyl bromides. Suitable solvents are N,N-dimethylformamide, N,N-diethylformamide, N-methyl-2-pyrrolidone, dimethylsulfoxide, toluene and xylene. The reaction is conducted at ambient temperature until complete or substantially complete. Potassium carbonate is favored as acid acceptor when N,N-dimethylformamide is used as solvent. However, other acid acceptors, inorganic and organic in nature, such as sodium carbonate, alkali metal hydrides or alkoxides; tertiary amines such as pyridine, triethylamine, N-methylmorpholine can also be used. The products are isolated by known procedures as, for example, by dilution with water or dilute aqueous acid followed by filtration of the product. A mixture of the 2-aralkyl and 1-aralkyl isomers is generally obtained. The isomers are separated by taking advantage of their solubility differences. The 5-LO inhibiting activity of the compounds of this invention is tested by a cell culture assay which determines the effect of said compounds on the metabolism of arachidonic acid and, therefore, their ability to inhibit the activity of 5-LO. The procedure is described by Jakschick et al., Prostaglandins 16 , 733-748 (1978). Because of their 5-LO inhibiting activity, the compounds of formulae I and II are effective agents for the prophylactic and therapeutic treatment of bronchoconstrictive and pulmonary diseases in man. When used for this purpose, said compounds are administered via the oral, parenteral or topical routes. The compounds may be administered per se but are preferably administered in the form of a composition, that is, in combination with a pharmaceutically acceptable carrier, which compositions may also comprise excipients, flavors, adjuvants, etc. in keeping with good pharmaceutical practice. The compositions may be in the form of solid, semi-solid or liquid dosage forms; such as, for instance, tablets, capsules, pills, powders, suppositories, solutions, elixirs, syrups, suspensions, creams, lozenges, pastes and sprays. As those skilled in the art recognize, the chosen route of administration of the herein described 5-LO inhibitors determines the form of composition to be used. In general, it is preferred to use a unit dosage form of the herein described inhibitors in order to achieve ease of treatment and administration of precise doses of the active compound. In general, the therapeutically effective compounds of this invention are present in such dosage forms at concentration levels ranging from 0.5% to 90% by weight of the total composition; i.e., in amount sufficient to provide the desired unit dose. The 5-LO inhibitor compounds of this invention may be administered in single or multiple doses. The particular route of administration and the dosage regimen will be determined by the attending physician in keeping with the condition of the individual to be treated and said individual's response to the treatment. In general, for oral administration, doses of from 10 mg to 1000 mg per day in single or multiple doses are sufficient. For parenteral administration, doses of from 5 mg to 750 mg per day are used in single or multiple doses. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful or deleterious side effects to occur provided that such higher dose levels are first divided into several smaller doses that are to be administered throughout the day. For purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and dicalcium phosphate may be employed along with various disintegrants such as starch and preferably potato or tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium sterate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection would also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and combinations thereof. For purposes of parenteral administration, solutions in either sesame or peanut oil or in aqueous propylene glycol may be employed, as well as sterile aqueous solutions of the corresponding water-soluble alkali metal or alkaline-earth metal salts previously enumerated. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular solutions are especially suitable for intravenous, intramuscular and subcutaneous injection purposes. Additionally, it is also possible to administer the aforesaid compounds topically and this may be preferably done by way of creams, salves, jellies, pastes or ointments, in accordance with standard pharmaceutical practice. This invention is still further illustrated by the following examples. EXAMPLE 1 4-Hydroxy-2-methyl-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-Dioxide Hemihydrate A mixture of 3-cyano-4-hydroxy-2-methyl-1,2-benzo-thiazine 1,1-dioxide (11.8 g), sodium azide (3.9 g) and ammonium chloride (3.2 g) in dimethylformamide (100 ml) was heated at 60-70° C. for 12 hours under nitrogen. The resulting mixture was poured into a mixture of water (400 ml), 6N HCl (30 ml) and ice (100 g) with stirring and the solid filtered off to give an off-white color product in 85% yield. Pure compound was obtained in 90% yield by dissolving the compound (3.53 g) in 0.5N NaOH (400 ml), treating with activated carbon (1.0 g) and adjusting pH to 2 with 6N HCl. In like manner the products of Preparations 4 and 5 are converted to the following compounds, respectively: (a) 2-ethyl-4-hydroxy-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide in 86% yield: EXAMPLE 1 (Contd) (b) 4-hydroxy-2-(2-methoxyethoxymethyl)-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide in 71.3% yield: (c) 4-hydroxy-2-(n-propyl)-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide: (d) 4-hydroxy-2-isopropyl-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide: EXAMPLE 2 4-Hydroxy-2-methyl-3-(2-methyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-Dioxide (a) 4-Acetoxy-2-methyl-3-(2-acetyltetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide A mixture of the title tetrazole of Example 1 (2.75 g) in acetic anhydride (30 ml) was stirred at room temperature for 16 hours. The resulting crystals were filtered off, washed with ether and dried in vacuo to give the title diacetyl derivative, 2.35 g. The filtrate was concentrated at 40° C. and triturated with dichloroethane to afford further product 0.75 g. Combined yield was 3.10 g (89%). (b) 4-Acetoxy-2-methyl-3-(2-methyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-dioxide A suspension of the product of (a) above (3.60 g), in toluene (40 ml) was refluxed for 2 hours, and the resulting solution concentrated to half volume and cooled to room temperature to give crystals. Filtration followed by drying in vacuo afforded colorless crystals, 3.29 g, in 99.1% yield of product (b). EXAMPLE 2 (Contd) (c) 4-Hydroxy-2-methyl-3-(2-methyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-dioxide To a solution of product (b) (2.218 g) in methanol (20 ml) was added 28% sodium methoxide (1.28 ml). After stirring at room temperature for 30 minutes, the solvent was stripped off and water (30 ml) was added. With vigorous stirring the pH was adjusted to ca. 1.5 with 6N HCl and the resulting solid granulated for 1 hour, filtered off, washed with water, and dried in vacuo to give compound (c), 1.903 g, 98% yield. EXAMPLE 3 4-Decanoyloxy-2-methyl-3-(2-nonyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-Dioxide A mixture of 4-hydroxy-2-methyl-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide hemihydrate (1.80 g) (6.25 mmoles) and decanoic anhydride (12 g) in toluene (20 ml) was refluxed for 16 hours. The solvent was stripped to dryness and the residue recrystallized from toluene (25 ml) to give the title compound in 68.4% yield. EXAMPLE 4 4-Hydroxy-2-methyl-3-(2-nonyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-Dioxide To a solution of the title compound of Example 3 (4.11 g) in methanol (20 ml) was added 28% sodium methoxide (1.28 ml). After stirring at room temperature for 30 minutes, the solvent was stripped off and water (30 ml) added. With vigorous stirring the pH was adjusted to ca. 1.5 by addition of 6N HCl and the resulting solid granulated for 1 hour at 20° C. It was removed by filtration, washed with water and dried in vacuo to give the title compound in 63% yield. EXAMPLE 5 4-Benzoyloxy-2-methyl-3-(2-methyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-Dioxide To a solution of 4-hydroxy-2-methyl-3-(2-methyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-dioxide, (0.155 g) in pyridine (0.5 ml) was added benzyl chloride (0.63 ml) at 5-10° C. After being stirred at room temperature for 1 hour, the mixture was diluted with dichloromethane, washed successively with dilute HCl, water and dilute sodium bicarbonate solution and dried over sodium sulfate to give, on concentration, crude solids 0.213 g. Recrystallization from toluene gave the title compound 0.156 g (74%). EXAMPLE 6 4-Benzoyloxy-2-methyl-3-(2-methyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-Dioxide To a suspension of 4-hydroxy-2-methyl-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide hemihydrate (2.88 g) in pyridine (10 ml) was added dropwise benzoyl chloride (1.02 ml) at 5-10° C. After being stirred at room temperature for 1 hour, the mixture was poured into 0.6N HCl (200 ml) with vigorous stirring. The resulting solids were collected by filtration and washed with water. The solids were dissolved in dichloromethane (100 ml), washed with water and dried over sodium sulfate to give crude 4-benzoyloxy-2-methyl-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide, 4.24 g. The crude product (0.205 g) was refluxed in acetic anhydride (5 ml) for 1 hour then concentrated under reduced pressure. Crystallization of the residue thus produced from toluene gave 0.067 g of title product identical to that of Example 5. EXAMPLE 7 3-(2-Cyclohexyl-1,3,4-oxadiazol-5-yl)-4-cyclohexyl-carbonyloxy-2-methyl-1,2-benzothiazine 1,1-Dioxide A mixture of 4-hydroxy-2-methyl-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide hemihydrate (0.72 g), cyclohexane-carboxylic acid (0.96 g) and N,N'-dicyclohexylcarbodiimide (1.55 g) in xylene (15 ml) was refluxed for 3 hours. The mixture was cooled, filtered and the filtrate diluted with dichloromethane (50 ml). The solution was washed with saturated sodium bicarbonate solution, then with water and dried over sodium sulfate. The solvent was replaced by toluene and resulting solid (Urea) was removed by filtration. The filtrate was concentrated and the residue crystallized from methanol to give 0.492 g (42%) of the title product. EXAMPLE 8 4-Hydroxy-2-methyl-3-(2-phenyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-Dioxide and 4-Benzoyloxy-2-methyl-3-(2-phenyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-Dioxide A mixture of 4-hydroxy-2-methyl-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide (0.576 g) and benzoic anhydride (1.81 g) in toluene (15 ml) was refluxed for 16 hours, then concentrated to a viscous oil which was solidified in n-hexane (10 ml) and filtered. The resulting solid and filtrate were treated separately. The solid was submitted to silica gel column chromatography (SiO₂, 20 g) and eluted with a mixed solvent (dichloromethane and ethylacetate 5:1) to give 0.420 g (45.8%) of the title benzoyl derivative. The above-mentioned filtrate was concentrated to an oil, and methanol (20 ml) and 28% sodium methoxide in methanol (2 ml) were added. After being stirred for 16 hours, the mixture was concentrated, acidified with 6N HCl and filtered. The solids were recrystallized from benzene to give 0.231 g (32.5%) of the title 4-hydroxy compound. EXAMPLE 9 4-Benzoyloxy-2-ethyl-3-(2-phenyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-Dioxide and 4-Hydroxy-2-ethyl-3-(2-phenyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-Dioxide Following the procedure of Example 8 but using stoichiometric amounts of 4-hydroxy-2-ethyl-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide as reactant in place of the corresponding 2-methyl derivative of Example 8 afforded the title 4-benzoyl derivative in 39% yield and the title 4-hydroxy derivative in 22.2% yield. 4-Benzoyl derivative: EXAMPLE 10 4-Benzoyloxy-2-(2-methoxyethoxymethyl)-3-(2-phenyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-Dioxide and 4-Hydroxy-2-(2-methoxyethoxymethyl-3-(2-phenyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-Dioxide Repetition of the procedure of Example 8, but using 4-hydroxy-2-(methoxyethoxymethyl)-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide as reactant in place of the 2-methyl derivative of said Example afforded the title compounds: 4-Benzoyl derivative in 43% yield: EXAMPLE 11 4-Benzoyloxy-3-(2-cyclohexyl-1,3,4-oxadiazol-5-yl)-2-methyl-1,2-benzothiazine 1,1-Dioxide (a) 3-(2-Cyclohexyl-1,3,4-oxadiazol-5-yl)-4-hydroxy-2-methyl-1,2-benzothiazine 1,1-dioxide The product of Example 7 was hydrolyzed according to the procedure of Example 4 to give the above-named hydroxy derivative in 90% yield. (b) Benzoylation of compound (a): The hydroxy compound (a) was benzoylated according to the procedure of Example 5 to give the title compound in 91% yield: EXAMPLE 12 4-Hydroxy-2-methyl-3-[2-(2-methoxyphenyl)-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-Dioxide (a) 4-(2-Methoxybenzoyloxy)-3-[2-(2-methoxyphenyl)-1,3,4-oxadiazol-5-yl]-2-methyl-1,2-benzothiazine 1,1-dioxide A mixture of 4-hydroxy-2-methyl-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide (0.72 g), o-anisic acid (1.14 g) and N,N'-dicyclohexylcarbodiimide (1.55 g) in xylene (15 ml) was refluxed for 3 hours, then cooled to 20° C. Needle crystals which formed were removed by filtration and the filtrate was diluted with dichloromethane, washed with saturated sodium bicarbonate solution and dried over sodium sulfate. Removal of the solvent in vacuo gave a solid residue which was crystallized from methanol to give 0.983 g (75.8%) of the ester derivative. (b) Hydrolysis of compound (a) to produce the title compound. The ester derivative of (a) was treated with sodium methoxide according to the procedure of Example 4 to give the title compound in 94% yield. EXAMPLE 13 4-Benzoyloxy-2-methyl-3-[2-(2-methoxyphenyl)-1,3,4-oxadiazol-5-yl]-1,2-benzothiazine 1,1-Dioxide Following the procedure of Example 5, 4-hydroxy-2-methyl-3-[2-(2-methoxyphenyl)-1,3,4-oxadiazol-5-yl]-1,2-benzothiazine 1,1-dioxide, the product of Example 12, was benzoylated to give the title compound in 74% yield. EXAMPLE 14 2-Methyl-3-(2-phenyl-1,3,4-oxadiazol-5-yl)-4-propionyloxy-1,2-benzothiazine 1,1-Dioxide Following the procedures of Example 5, but substituting propionyl chloride for benzoyl chloride, 4-hydroxy-2-methyl-3-(2-phenyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-dioxide was acylated to give the title product. EXAMPLE 15 4-Benzoyloxy-3-(2-ethyl-1,3,4-oxadiazol-5-yl)-2-methyl-1,2-benzothiazine 1,1-Dioxide (a) Following the procedure of Example 4, 2-methyl-3-(2-ethyl-1,3,4-oxadizol-5-yl)-4-propionyloxyl-1,2-benzothiazine 1,1-dioxide was hydrolyzed to the corresponding 4-hydroxy derivative in 96.3% yield. (b) The 4-hydroxy compound of step (a) was benzoylated according to the procedure of Example 6 to give the title product in 72% yield. EXAMPLE 16 4-Acetoxy-3-(2-benzyltetrazol-5-yl)-2-methyl-1,2-benzothiazine 1,1-Dioxide (a) 3-(2-Benzyltetrazol-5-yl)-4-hydroxy-2-methyl-1,2-benzothiazine 1,1-dioxide To a mixture of 4-hydroxy-2-methyl-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide hemihydrate (2.88 g) and potassium carbonate (0.69 g) in dimethylformamide (10 ml) was added benzylbromide (1.80 g) and stirring was continued for 16 hours. The mixture was poured into 0.15N NCl (75 ml), and the resulting solid collected by filtration, washed with water, and then with n-hexane to give crude product (3.59 g) which was recrystallized from toluene to give colorless crystals, 2.81 g (74.4%). (b) Acylation of compound (a): A mixture of compound (a) above (0.30 g) and acetic anhydride (5 ml) was refluxed for 4 hours and then concentrated. The residual oil solidified upon addition of n-hexane. After removal of the solvent by decantation, the solid was crystallized from toluene, filtered off and dried in vacuo to give 0.275 g (90.5%) of the title compound. EXAMPLE 17 4-Benzoyloxy-3-(2-benzyltetrazol-5-yl)-2-methyl-1,2-benzothiazine 1,1-Dioxide A mixture of the product of Example 16 (a) (0.6 g) and benzoic anhydride (1.20 g) in xylene (20 ml) was refluxed for 12 hours then concentrated to a viscous oil, which was dissolved in dichloromethane (50 ml) and washed with 20% NaOH aqueous solution to remove starting material. The organic layer was washed with water, dried over sodium sulfate and concentrated to give a solid which was recrystallized from toluene to afford 0.587 g (83.1%) of the title product. EXAMPLE 18 4-Hydroxy-3-[(2-benzyl)tetrazol-5-yl]-2-methyl-1,2-benzothiazine 1,1-Dioxide and 1-Benzyl Isomer A suspension of 4-hydroxy-2-methyl-3-(tetrazol-5-yl)-2H-1,2-benzothiazine 1,1-dioxide hemihydrate (20 g) in toluene (400 ml) was refluxed in a Dean-Stark apparatus until water removal was complete. Bis (tri-n-butyltin)oxide (35.4 ml) was then added and the reaction mixture refluxed for 30 minutes then cooled to room temperature. Benzyl bromide (8.67 ml) was then added to the clear reaction mixture which was then refluxed for 16 hours. Concentration of the mixture under reduced pressure gave a two-phase oil which was washed with n-hexane (200 ml × 4) to give a dark solid (32.5 g). The solid was dissolved in trifluoroacetic acid (62 ml) and the solution cooled to 0° C. Addition of methanol (156 ml) to the solution gave a precipitate comprising an isomeric mixture of 4-hydroxy-3-[(1-benzyl)tetrazol-5-yl]-2-methyl-1,2-benzothiazine 1,1-dioxide with its 2-benzyl isomer (15.64 g). Ratio of 1-benzyl to 2-benzyl = 1:0.3. EXAMPLE 19 4-Acetoxy-3-[(2-benzyl)tetrazol-5-yl]-2-methyl-1,2-benzothiazine 1,1-Dioxide and 1-Benzyl Isomer To a solution of 4-hydroxy-2-methyl-3-(5-tetrazolyl)-2H-1,2-benzothiazine 1,1-dioxide hemihydrate (18.0 g) and potassium carbonate (4.32 g), in N,N-dimethylformamide (63 ml) was added benzylbromide (7.81 ml). After being stirred for 16 hours at room temperature, the mixture was poured into 1N HCl (500 ml) with stirring. The resulting solids were filtered off and washed with water (100 ml) and then with petroleum ether (50 ml). The wet solids were recrystallized from toluene (150 ml) to give 4-hydroxy-3-[(2-benzyl)tetrazol-5-yl]-2-methyl-1,2-benzothiazine 1,1-dioxide (16.70 g). The mother liquor contains the said compound and its 1-benzyl isomer. It was concentrated to an oil (6.03 g), which was treated with acetic anhydride (30 ml) at 110° C. for 1.5 hours, concentrated and crystallized in toluene (30 ml), to afford 4-acetoxy-3-[(2-benzyl)-tetrazol-5-yl]-2-methyl-1,2-benzothiazine 1,1-dioxide (1.31 g). The resulting mother liquor was concentrated to a viscous oil diluted with toluene (10 ml) and seeded. The resulting crystals were filtered off and recrystallized from toluene (24 ml) to give 4-acetoxy-[(1-benzyl)tetrazol-5-yl]-2-methyl-1,2-benzothiazine 1,1-dioxide (0.602 g). EXAMPLE 20 4-Acetoxy-3-[(1-benzyl)tetrazol-5-yl)-2-methyl-1,2-benzothiazine 1,1-Dioxide A mixture of the 1-benzyl isomer of Example 18 and acetic anhydride (100 ml) was refluxed for ten minutes then concentrated under reduced pressure to an oil. Addition of toluene (65 ml) to said oil afforded the title product as crystals (5.52 g; 76%; overall yield of 20% based upon the reactant of Example 18). It is identical to the product of Example 19. EXAMPLE 21 4-Hydroxy-3[(2-(4-methoxybenzyl))tetrazol-5-yl]-2-methyl-1,2-benzothiazine 1,1-Dioxide To a mixture of 4-hydroxy-2-methyl-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide hemihydrate (2.88 g, 10 mmole), potassium carbonate (0.69 g) and sodium iodide (0.5 g), in N,N-dimethylformamide (10 ml) was added 4-methoxybenzylchloride (1.72 g). It was stirred for four hours at room temperature then poured into water (200 ml) with stirring, and the resulting solids filtered off, washed with water and dried in vacuo to afford 3.44 g of a mixture comprising the title compound and the corresponding 1-isomer. Recrystallization from toluene gave the title compound. EXAMPLE 22 3-[(2-Benzyl)tetrazol-5-yl]-2-ethyl-4-hydroxy-1,2-benzothiazine 1,1-Dioxide A mixture of 2-ethyl-4-hydroxy-3-(tetrazol-5-yl)-1,2-benzothiazine 1,1-dioxide (0.5 g), potassium carbonate (0.120 g) and benzylbromide (0.21 ml) in dimethylformamide was stirred at room temperature for 16 hours, then poured into water (30 ml). The resulting solids were filtered off, washed with water and dried in vacuo to give crude product (0.638 g), which was recrystallized from toluene to afford the title compound (0.457 g, 70%). EXAMPLE 23 4-Acetoxy-2-methyl-3-(2-nonyl-1,3,4-oxadiazol-5-yl-1,2-benzothiazine 1,1-dioxide A mixture of the product of Example 4 (0.50 g) and acetic anhydride (2 ml) was refluxed for about ten minutes. The reaction mixture was concentrated in vacuo . Crystallization of the residue from methanol, after filtration and drying, gave the title compound (0.493 g). M.P.: 118-119°C. EXAMPLE 24 4-Cyclopentancarbonyloxy-2-ethyl-3-(2-[phenyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-dioxide A mixture of 2-ethyl-4-hydroxy-3-(2-phenyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-dioxide (0.739 g), cyclopentanecarboxylic acid (0.34 g) and N,N'-dicylcohexylcarbodiimide (1.55 g) in pyridine (2.5 ml) was stirred at room temperature for 16 hours. Water (7 ml) was added to the reaction mixture and the solid thus formed was filtered and washed with water. The solid was then dissolved in chloroform and filtered. The filtrate was concentrated. The residue was recrystallized from toluene to give the title compound (0.776 g). M.P.: 194-196°C. EXAMPLE 25 The following compounds were produced according to Examples indicated from appropriate corresponding reactants: EXAMPLE 25 (Contd) EXAMPLE 26 The compounds listed below were prepared according to Examples indicated from appropriate corresponding reactants: EXAMPLE 27 A dry solid pharmaceutical composition is prepared by blending the following materials together in the proportions by weight specified below: After the dried composition is thoroughly blended, tablets are punched from the resulting mixture, each tablet being of such size that it contains 100 mg of the active ingredient. Other tablets are also prepared in a similar manner containing 5, 10, 25 and 50 mg of the active ingredient, respectively, by merely using the appropriate amount of the appropriate 5-LO inhibitor compound in each case. EXAMPLE 28 A dry solid pharmaceutical composition is prepared by combining the following materials together in the proportions by weight indicated below: The dried solid mixture so prepared is then thoroughly agitated so as to obtain a powdered product that is completely uniform. Soft elastic and hard-filled gelatin capsules containing this pharmaceutical composition are then prepared, employing a sufficient quantity of material in each case so as to provide each capsule with 250 mg of the active ingredient. EXAMPLE 29 Oral Suspension One thousand ml of an aqueous suspension, containing 100 mg of 4-benzoyloxy-2-(2-methoxyethoxymethyl)-3-(2-phenyl-1,3,4-oxadiazol-5-yl)-1,2-benzothiazine 1,1-dioxide in each 5 ml dose, is prepared using the following ingredients: All ingredients except the benzothiazine 1,1-dioxide compound are thoroughly dispersed in sufficient water to make 850 ml of suspension. The benzothiazine 1,1-dioxide compound is then stirred in until uniformly distributed and sufficient water added to make 1000 ml. PREPARATION 1 o-Carbomethoxy-N-cyanomethylbenzenesulfonamide To a suspension of N-cyanomethylsaccharin (276 g) in methanol (1000 ml) was added dropwise 28% sodium methoxide (145 ml) over 30 minutes at 5-10° C. After stirring at 5-10° C. for 1 hour, 6N HCl (ca. 230 ml) was added dropwise maintaining the temperature at 10-15° C. The resulting crystals were collected by filtration, washed with water and dried in vacuo at 50° C. for 16 hours to give o-carbomethoxy-N-cyanomethylbenzenesulfonamide, 264 g (78.7%). PREPARATION 2 o-Carbomethoxy-N-cyanomethyl-N-methylbenzenesulfonamide To a mixture of o-carbomethoxy-N-cyanomethylbenzenesulfonamide (116 g) and sodium hydroxide (16.8 g) in water (80 ml) and acetone (400 ml) was added methyliodide (28 ml) at 20-25° C. After stirring for 3 hours at 20° C., the solvent was stripped off to give a viscous oil. Water (400 ml) was added and the mixture extracted with dichloromethane. The resulting extract was washed with water, dried over sodium sulfate and concentrated to give the product as a viscous oil, 108.2 g (88%). PREPARATION 3 3-Cyano-4-hydroxy-2-methyl-1,2-benzothiazine 1,1-Dioxide To a solution of o-carbomethoxy-N-cyanomethyl-N-methylbenzenesulfonamide (108 g) in toluene (600 ml) was added 28% sodium methoxide-methanol solution (83 ml) with vigorous stirring. After 2 hours the solvent was evaporated to ca. 400 ml and water (800 ml) added to dissolve the viscous residue. The pH was adjusted to ca. 2 with 6N HCl. The resulting crystals were granulated for 1 hour, filtered off, washed with water and dried in vacuo to give the title product, 77.2 g (81.1%). Purified product was obtained in 75% yield by dissolving the compound (3.3 g) in isopropanol, followed by dropwise addition of water (35 ml). PREPARATION 4 3-Cyano-2-ethyl-4-hydroxy-1,2-benzothiazine 1,1-Dioxide A mixture of o-carbomethoxy-N-cyanomethylbenzene-sulfonamide (6.25 g) (0.025 moles), ethyl iodide (2 ml) and potassium carbonate (1.73 g) in dimethylformamide (30 ml) was stirred at room temperature for 48 hours at at 50° C. for 2 hours. The resulting mixture was poured into water (50 ml) and extracted with dichloromethane. The extract was washed with water, dried over sodium sulfate and concentrated to give an oil 6.69 g. The oil was dissolved in toluene (33 ml), then 28% sodium methoxide in methanol (4.6 ml) was added. After being stirred at 20° C. for 16 hours, the mixture was concentrated to a viscous oil, to which was added water (50 ml) and then 6N HCl to pH 2.0. The resulting solid was filtered off, washed with water and dried in vacuo to give colorless crystals (4.83 g). Recrystallization from dichloroethane afforded colorless needles of desired product, 4.215 g (67.4%). PREPARATION 4 (Contd) In like manner, but using n-propyl iodide or isopropyl iodide in place of ethyl iodide, the corresponding 2-n-propyl- and 2-isopropyl compounds are prepared: 3-cyano-2-n-propyl-4-hydroxy-1,2-benzothiazine 1,1-dioxide 3-cyano-2-isopropyl-4-hydroxy-1,2-benzothiazine 1,1-dioxide PREPARATION 5 3-Cyano-4-hydroxy-2-(2-methoxyethoxymethyl)-1,2-benzothiazine 1,1-Dioxide To a solution of o-carbomethoxy-N-cyanomethylbenzenesulfonamide (6.25 g) in dichloromethane (50 ml) was added triethylamine (2.5 g) and then beta-methoxy-ethoxymethyl chloride (3.12 g) at 5-10° C. After being stirred for 1 hour at room temperature, the mixture was washed with water, dried over sodium sulfate and concentrated. To the resulting oil was added toluene (33 ml) and then 28% sodium methoxide in methanol (4.6 ml) and stirring was continued for an additional 16 hours at room temperature. The mixture was extracted with water (50 ml) and the aqueous layer was acidified to pH 2 with 6N HCl and extracted with dichloromethane. The resulting organic layer was washed with water, dried over sodium sulfate and concentrated to a viscous oil, which was submitted to silica gel column chromatography (SiO₂, 100 g) and eluted with a mixed solvent (CH₂Cl₂:CH₃OH 4:1) to give the title product as a viscous oil.

Claims: Claims for the following Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE A compound having the formula I or II wherein R¹ is alkyl having from 1 to 8 carbon atoms or -(CH₂) m -O-(CH₂) n OR⁶ where m is an integer from 1 to 4, n is an integer from 2 to 4 and R⁶ is alkyl having from one to six carbon atoms; R² is hydrogen, alkanoyl having from 2 to 15 carbon atoms, cycloalkylcarbonyl having from 3 to 8 carbon atoms in the cycloalkyl moiety, benzoyl or benzoyl ring substituted with F, Cl, Br, I, CF₃, CH₃, NO₂ or CH₃O; R³ is alkyl having from 1 to 15 carbon atoms, cycloalkyl having from 3 to 8 carbon atoms, phenyl or phenyl substituted with F, Cl, Br, I, CF₃, CH₃, NO₂ or CH₃O; R⁴ is hydrogen, alkanoyl having from 2 to 15 carbon atoms, benzoyl or benzoyl ring substituted with F, Cl, Br, I, CF₃, CH₃, NO₂, CH₃O; and R⁵ is hydrogen, alkyl, having from 1 to 15 carbon atoms, alkanoyl having from 2 to 16 carbon atoms, cycloalkylcarbonyl having from 3 to 8 carbon atoms in the cycloalkyl moiety, phenyl(C₁-C₄ alkyl) or benzoyl, said phenylalkyl or benzoyl optionally being ring substituted with F, Cl, Br, I, CF₃, NO₂, CH₃ or CH₃O. A compound according to claim 1 of formula I wherein R¹ is alkyl having from 1 to 3 carbon atoms, R² is hydrogen, alkanoyl having from 2 to 10 carbon atoms, benzoyl or cyclohexylcarbonyl, and R³ is alkyl having from 7 to 15 carbon atoms, phenyl or tolyl. A compound according to claim 2 wherein R² is hydrogen, benzoyl, acetyl or cyclohexylcarbonyl. The compound according to claim 3 wherein R¹ is ethyl, R² is acetyl and R³ is phenyl or m-tolyl. The compound according to claim 3 wherein R¹ is ethyl, R² is cyclohexylcarbonyl and R³ is phenyl. The compound according to claim 3 wherein R¹ is methyl, R² is cyclohexylcarbonyl and R³ is nonyl. The compound according to claim 3 wherein R¹ is ethyl, R² is benzoyl and R³ is phenyl. A compound according to claim 1 of formula II wherein R¹ is is alkyl having from 1 to 3 carbon atoms, R⁴ is acetyl and R⁵ is alkyl having from 8 to 10 carbon atoms, methylbenzyl or methoxybenzyl. The compound according to claim 8 wherein R¹ is ethyl, R⁴ is acetyl and R⁵ is nonyl. The compound according to claim 8 wherein R¹ is n-propyl, R⁴ is acetyl and R⁵ is 4-methoxybenzyl. The compound according to claim 8 wherein R¹ is ethyl, R⁴ is acetyl and R⁵ is 3-methylbenzyl. A compound according to claim 1 of formula II wherein R¹ is methyl, ethyl or n-propyl and each of R⁴ and R⁵ is hydrogen. A compound according to claim 1 for use in the treatment of adult respiratory distress syndrome in mammals. A pharmaceutical composition comprising a compound according to claim 1 in a pharmaceutically acceptable carrier. A compound having the formula VI where R¹ is as defined in claim 1. Claims for the following Contracting State : AT A process for making a compound having the formula I wherein R¹ is alkyl having from 1 to 8 carbon atoms or -(CH₂) m -O-(CH₂) n OR⁶ where m is an integer from 1 to 4, n is an integer from 2 to 4 and R⁶ is alkyl having from one to six carbon atoms; R² is hydrogen, alkanoyl having from 2 to 15 carbon atoms, cycloalkylcarbonyl having from 3 to 8 carbon atoms in the cycloalkyl moiety, benzoyl or benzoyl ring substituted with F, Cl, Br, I, CF₃, CH₃, NO₂ or CH₃O; and R³ is alkyl having from 1 to 15 carbon atoms, cycloalkyl having from 3 to 8 carbon atoms, phenyl or phenyl substituted with F, Cl, Br, I, CF₃, CH₃, NO₂, or CH₃O; which comprises (a) thermal degradation of a compound having the formula II wherein R⁴ is hydrogen, alkanoyl having from 2 to 15 carbon atoms, benzoyl or benzoyl being ring substituted with F, Cl, Br, I, CF₃, CH₃, NO₂ or CH₃O; and R⁵ is alkanoyl having from 2 to 16 carbon atoms, cycloalkylcarbonyl having from 3 to 8 carbon atoms in the cycloalkyl moiety or benzoyl or benzoyl being ring substituted with F, Cl, Br, I, CF₃, CH₃, CH₃O or NO₂; (b) when a compound of formula I wherein R² is hydrogen is required, subjecting a compound of formula I wherein R² is other than hydrogen to alkaline hydrolysis; (c) when a compound of formula I wherein R² is other than hydrogen is required, acylating a compound of formula I wherein R² is hydrogen with an appropriate acylating agent. A process according to claim 1 wherein R¹ is alkyl having from 1 to 4 carbon atoms, R² is hydrogen, alkanoyl having from 2 to 15 carbon atoms, benzoyl, cyclohexylcarbonyl or methoxybenzoyl; and R³ is alkyl having from 7 to 15 carbon atoms, phenyl, cyclohexyl, methoxyphenyl or tolyl. A process according to claim 2 wherein R¹ is ethyl, R² is acetyl, cyclohexylcarbonyl or benzoyl; and R³ is alkyl having from 7 to 11 carbon atoms, phenyl or tolyl. A process for making a compound having the formula II where R¹ is alkyl having from 1 to 8 carbon atoms or -(CH₂) m -O-(CH₂) n -OR₆ where m is an integer from 1 to 4, n is an integer from 2 to 4 and R⁶ is alkyl having from one to six carbon atoms; R⁴ is hydrogen, alkanoyl having from 2 to 15 carbon atoms, benzoyl or benzoyl ring substituted with F, Cl, Br, I, CF₃, CH₃, CH₃O; and R⁵ is alkanoyl having from 2 to 16 carbon atoms, cycloalkylcarbonyl having from 3 to 8 carbon atoms in the cycloalkyl moiety; benzoyl or benzoyl being ring substituted with F, Cl, Br, I, CF₃, CH₃, NO₂ or CH₃O; which comprises (a) acylating with an appropriate acylating agent a compound having the formula VI wherein R¹ is as defined above; (b) when a compound of formula II wherein R⁴ is other than hydrogen is required, acylating a compound of formula II wherein R⁴ is hydrogen with an appropriate acylating agent. A process according to claim 4 wherein R¹ is alkyl having from 1 to 3 carbon atoms or methoxymethyl and R⁴ is acetyl, cyclohexylcarbonyl or benzoyl; and R⁵ is alkanoyl having from 7 to 15 carbon atoms, benzoyl, methylbenzoyl or methoxybenzoyl. A process for making a compound having the formula II wherein R¹ is alkyl having from 1 to 8 carbon atoms or -(CH₂) m -O-(CH₂) n -OR₆ where m is an integer from 1 to 4, n is an integer from 2 to 4 and R⁶ is alkyl having from one to six carbon atoms; and R⁵ is alkyl having from 1 to 15 carbon atoms, or phenyl(C₁-C₄ alkyl) optionally ring substituted with F, Cl, Br, I, CF₃, NO₂, CH₃ or CH₃O; which comprises alkylating or aralkylating a compound having the formula VI wherein R¹ is as defined above; and, if desired, acylating the compound to produce a compound having the formula II wherein R¹ and R⁵ are as defined above; and R⁴ is alkanoyl having from 2 to 16 carbon atoms, benzoyl or benzoyl ring substituted with F, Cl, Br, I, CF₃, CH₃, NO₂ or CH₃O. A process for making a compound having the formula VI wherein R¹ is as previously defined in claim 1 and; which comprises reacting a compound of the formula V wherein R¹ is as defined above with sodium azide in the presence of an acid addition salt of ammonia or an amine in a reaction-inert solvent.

Inventors: NAGAKURA, ISAO, NAKANISHI, SUSUMU
Applicants: PFIZER CORPORATION
Application year: 1986
Main classification: C07D417
IPC codes: C12N9, A61P37, C07D417, A61K31, A61P43